Volume | 57,002 |
|
|||||
News | - | ||||||
Day High | 4.64 | Low High |
|||||
Day Low | 4.48 |
Share Name | Share Symbol | Market | Stock Type |
---|---|---|---|
Achieve Life Sciences Inc | ACHV | NASDAQ | Common Stock |
Open Price | Low Price | High Price | Close Price | Previous Close |
---|---|---|---|---|
4.57 | 4.48 | 4.64 | 4.61 | 4.575 |
Trades | Shares Traded | VWAP | Financial Volume | Average Volume | 52 Week Range |
---|---|---|---|---|---|
1,245 | 57,002 | US$ 4.60 | US$ 262,492 | - | 3.03 - 10.30 |
Last Trade | Type | Quantity | Price | Currency |
---|---|---|---|---|
16:42:15 | 75 | US$ 4.77 | USD |
Achieve Life Sciences Inc Financials
Market Cap | Shares in Issue | Float | Revenue | Profit/Loss | EPS | PE Ratio |
---|---|---|---|---|---|---|
97.36M | 21.17M | - | 0 | -29.82M | -1.41 | - |
Short Interest | Dividends Per Share | Dividend Yield | Ex-Div Date | Insider B/S | Insider % Owned |
---|---|---|---|---|---|
- | - | - | - |
Achieve Life Sciences News
{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}} |
Loading Messages....
Historical ACHV Price Data
Period † | Open | High | Low | VWAP | Avg. Daily Vol | Change | % |
---|---|---|---|---|---|---|---|
1 Week | 4.55 | 4.66 | 4.35 | 4.49 | 51,368 | 0.15 | 3.30% |
1 Month | 4.64 | 4.6993 | 4.02 | 4.48 | 66,399 | 0.06 | 1.29% |
3 Months | 4.91 | 5.00 | 3.82 | 4.43 | 97,912 | -0.21 | -4.28% |
6 Months | 3.99 | 5.98 | 3.03 | 4.18 | 90,231 | 0.71 | 17.79% |
1 Year | 7.93 | 10.30 | 3.03 | 5.21 | 94,009 | -3.23 | -40.73% |
3 Years | 10.97 | 11.75 | 2.00 | 6.29 | 98,614 | -6.27 | -57.16% |
5 Years | 4.00 | 23.24 | 0.225744 | 2.11 | 523,070 | 0.70 | 17.50% |
Achieve Life Sciences Description
Achieve Life Sciences Inc is a specialty pharmaceutical company committed to advancing cytisinicline as a widely available treatment option to help people battling nicotine addiction. It is an established smoking cessation treatment that has been approved and marketed in Central and Eastern Europe. Achieve's focus is to address the global smoking health epidemic through the development and commercialization of cytisinicline. |